Hill-Rom (NYSE:HRC) was upgraded by stock analysts at Raymond James Financial from a “market perform” rating to an “outperform” rating in a research note issued on Wednesday, January 3rd, Marketbeat Ratings reports. The firm currently has a $94.00 price objective on the medical technology company’s stock. Raymond James Financial’s price target would suggest a potential upside of 6.96% from the company’s current price.

A number of other research firms have also recently issued reports on HRC. KeyCorp reiterated a “buy” rating and issued a $94.00 target price on shares of Hill-Rom in a research note on Thursday, December 21st. Morgan Stanley cut shares of Hill-Rom from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 2nd. They noted that the move was a valuation call. ValuEngine lowered shares of Hill-Rom from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Stifel Nicolaus reaffirmed a “buy” rating and set a $92.00 target price on shares of Hill-Rom in a research report on Wednesday, November 29th. Finally, Bank of America reaffirmed a “hold” rating on shares of Hill-Rom in a research report on Wednesday, November 22nd. Five investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $95.38.

Shares of Hill-Rom (HRC) opened at $87.88 on Wednesday. The company has a current ratio of 1.75, a quick ratio of 1.29 and a debt-to-equity ratio of 1.39. The company has a market cap of $5,837.85, a P/E ratio of 21.89, a P/E/G ratio of 1.48 and a beta of 1.19. Hill-Rom has a fifty-two week low of $57.45 and a fifty-two week high of $91.11.

Hill-Rom (NYSE:HRC) last posted its earnings results on Friday, January 26th. The medical technology company reported $0.92 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.79 by $0.13. The firm had revenue of $669.70 million during the quarter, compared to analysts’ expectations of $670.00 million. Hill-Rom had a net margin of 7.14% and a return on equity of 20.24%. The company’s revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.75 earnings per share. analysts anticipate that Hill-Rom will post 4.59 EPS for the current year.

In other news, CEO John J. Greisch sold 125,241 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $82.59, for a total value of $10,343,654.19. Following the sale, the chief executive officer now owns 280,851 shares of the company’s stock, valued at approximately $23,195,484.09. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO John J. Greisch sold 100,000 shares of the company’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $82.82, for a total transaction of $8,282,000.00. Following the transaction, the chief executive officer now owns 230,851 shares in the company, valued at approximately $19,119,079.82. The disclosure for this sale can be found here. Insiders sold a total of 226,241 shares of company stock worth $18,708,644 in the last three months. Insiders own 1.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Stifel Financial Corp lifted its position in Hill-Rom by 0.5% during the 2nd quarter. Stifel Financial Corp now owns 4,379 shares of the medical technology company’s stock worth $349,000 after buying an additional 23 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in Hill-Rom by 0.5% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 8,734 shares of the medical technology company’s stock valued at $695,000 after purchasing an additional 46 shares during the period. Utah Retirement Systems lifted its position in Hill-Rom by 0.8% during the 2nd quarter. Utah Retirement Systems now owns 12,013 shares of the medical technology company’s stock valued at $956,000 after purchasing an additional 100 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Hill-Rom by 10.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,201 shares of the medical technology company’s stock valued at $175,000 after purchasing an additional 204 shares during the period. Finally, ETRADE Capital Management LLC lifted its position in Hill-Rom by 4.6% during the 2nd quarter. ETRADE Capital Management LLC now owns 6,940 shares of the medical technology company’s stock valued at $552,000 after purchasing an additional 303 shares during the period. Institutional investors and hedge funds own 81.38% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was reported by Marea Informative and is the sole property of of Marea Informative. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.mareainformativa.com/hill-rom-hrc-lifted-to-outperform-at-raymond-james-financial-updated-updated-updated/126245/.

About Hill-Rom

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Analyst Recommendations for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.